AORT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AO

Mkt Cap

$1.06B

Volume

345.98K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top HoldingYarger Wealth Strategies made a contrarian bet by acquiring 634,223 shares of Artivion (AORT), making it the fund's largest holding at 9.35% of assets under management. The $25.02 million investment comes as Artivion shares have declined 21.4% over the past year, underperforming the S&P 500 by 46.6 percentage points. The medtech company specializes in cardiac and vascular surgical products.The Motley Fool · May 17, 2026

Beyond The Numbers: 7 Analysts Discuss Artivion StockArtivion Inc, a cardiac and vascular solutions company, has received mixed analyst ratings with an average 12-month price target of $43.83. The company shows strong financial performance with impressive revenue growth, net margin, and efficient asset utilization.Benzinga · Sep 29, 2025

Artivion (AORT) Q2 EPS Jumps 243%Artivion reported strong Q2 2025 financial results, with non-GAAP EPS of $0.24, exceeding expectations and growing 243% year-over-year. Revenue reached $113.0 million, a 15% increase, and the company raised its full-year 2025 guidance.The Motley Fool · Aug 7, 2025

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Artivion, Inc. Customers Whose Data May Have Been CompromisedArtivion, Inc. experienced a data breach on November 20-21, 2024, where an unauthorized third party accessed network files potentially containing sensitive personal information like Social Security Numbers and driver's license details.GlobeNewswire Inc. · Jul 14, 2025

$536.73 Bn Organ Preservation Solution Market Strategies and Opportunities to 2033: New R&D Center to Revolutionize Organ Preservation Techniques and Enhance Global Healthcare SolutionsThe global organ preservation solution market is expected to grow from $273.96 million in 2023 to $536.73 million in 2033, driven by factors such as the rise in organ transplant surgeries, favorable government regulations, and the growing prevalence of chronic diseases. The report highlights key market trends, including strategic investments in R&D, partnerships, and the establishment of new research centers to drive innovation in organ preservation techniques.GlobeNewswire Inc. · Feb 12, 2025

Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - SNS InsiderThe global Wound Closure Market is expected to grow from $15.17 billion in 2023 to $26.63 billion by 2032, driven by increasing chronic wounds, aging population, and rising healthcare infrastructure. Sutures and hemostatic agents are the key product types, with general surgery and cardiology being the major application areas.GlobeNewswire Inc. · Feb 10, 2025

A Glimpse Into The Expert Outlook On Artivion Through 4 AnalystsIn the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Frank Takkinen Lake Street Raises Buy $30.00 $28.00 Rick Wise Stifel Raises Buy $25.00 $22.00 Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.comBenzinga · Jul 2, 2024

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Zacks Investment Research · Jun 12, 2024

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.Zacks Investment Research · May 8, 2024

Breaking Down Artivion: 4 Analysts Share Their Views4 analysts have expressed a variety of opinions on Artivion (NYSE:AORT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.5, a high estimate of $30.00, and a low estimate of $22.00. Marking an increase of 10.87%, the current average surpasses the previous average price target of $23.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Raises Buy $30.00 $25.00 Mike Matson Needham Maintains Buy $25.00 $25.00 Rick Wise Stifel Raises Buy $22.00 $20.00 Mike Matson Needham Raises Buy $25.00 $22.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. ...Full story available on Benzinga.comBenzinga · May 7, 2024

AO

AORTArtivion, Inc.

AORT

Pay with—

Available Balance0.00

Your PositionYou don't own any AORT yet.

Related Tickers

Earnings